2013
Topical Tazarotene for the Treatment of Ectropion in Ichthyosis
Craiglow BG, Choate KA, Milstone LM. Topical Tazarotene for the Treatment of Ectropion in Ichthyosis. JAMA Dermatology 2013, 149: 598-600. PMID: 23677086, PMCID: PMC3809825, DOI: 10.1001/jamadermatol.2013.239.Peer-Reviewed Case Reports and Technical NotesConceptsTreatment of ectropionTopical tazaroteneBilateral lower eyelid ectropionGroup of patientsStandard of carePotential treatment optionLower eyelid ectropionPotential effective treatmentTopical retinoidsMedical therapySurgical interventionTreatment optionsEyelid ectropionCosmetic consequencesEffective treatmentCertain subtypesPatientsEctropionPersistent improvementDaily applicationTazaroteneAdditional studiesAdverse effectsRetinoidsIchthyosis
2009
First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder
Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, Hansen CD, Eliason MJ, Srivatsa GS, Kornbrust DJ, Smith FJ, McLean WI, Milstone LM, Kaspar RL. First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin Disorder. Molecular Therapy 2009, 18: 442-446. PMID: 19935778, PMCID: PMC2839285, DOI: 10.1038/mt.2009.273.Peer-Reviewed Original ResearchConceptsPachyonychia congenitaPhase Ib clinical trialSubjective patient assessmentPhase Ib trialDose-escalation trialClinical efficacy measuresAutosomal dominant syndromeIb trialAdverse eventsWashout periodPatient assessmentEfficacy measuresPlantar callusClinical trialsPlantar keratodermaOpposite footSkin disordersSkin diseasesClinical settingDominant syndromeSatisfactory treatmentAdditional studiesTrialsGenetic disordersSiRNA